Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference

被引:144
作者
Bjorner, Jakob B.
Wallenstein, Gene V.
Martin, Marie C.
Lin, Peggy
Blaisdell-Gross, Bonnie
Piech, Catherine Tak
Mody, Samir H.
机构
[1] Qual Metr Inc, Lincoln, RI 02865 USA
[2] Ortho Biotech Clin Affairs LLC, Bridgewater, NJ USA
关键词
anemia; fatigue; MCID; MID; SF-36 Vitality scale;
D O I
10.1185/030079907X178757
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To propose the minimally important difference (MID) for the SF-36 Vitality (VT) scale by evaluating the association of score differences with clinical conditions and functional outcomes. Methods: Analyses were performed on data from the Medical Outcomes Study (n = 3445). The first analyses regressed VT scores (0-100 scale) on chronic conditions that cause fatigue in order to determine the impact of each condition on VT. The second set of analyses examined the relationship between baseline VT scores and other outcomes at baseline, 1-year, and 7-year follow-up. Results: VT scores were significantly reduced in patients with anemia [5 points (95% CI 2-9 points)], CHF [6 (3-9) points], and COPD [6 (3-9) points]. Decreases in VT score were significantly associated with increased odds of negative outcomes, including inability to work due health at baseline [OR (5 points) = 1.27 (95% CI 1.24-1.31), OR (10 points) = 1.62 (1.54-1.71)], job loss at 1 year [OR (5) = 1.13 (1.08-1.19), OR (10) = 1.28 (1.17-1.41)], hospitalization at 1 year [OR (5) = 1.08 (1.05-1.11), OR (10) = 1.17 (1.10-1.23)], short-term mortality [0-18 months-Hazard Ratio (HR) (5) = 1.10-1.71, HR (10) = 1.21-2.39, depending on VT level] and long-term mortality [19+ months-HR (5) =1.05-1.31, HR (10) = 1.10-1.54]. The mortality risk increase was largest at low VT levels. Conclusions: VT decrements of 5-10 points were seen for diseases known to cause fatigue. Further, differences of 5-10 points in the VT score were associated with significant increased risk of negative outcomes. We recommend an MID of 5 points for analyses of groups with VT scores below average. For follow-up of individual patients, we recommend a 10-point difference as important.
引用
收藏
页码:731 / 739
页数:9
相关论文
共 27 条
[1]   Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening [J].
Cella, D ;
Hahn, EA ;
Dineen, K .
QUALITY OF LIFE RESEARCH, 2002, 11 (03) :207-221
[2]  
Cohen J, 1988, STAT POWER BEHAV SCI
[3]   THE EFFECTS OF ANTIHYPERTENSIVE THERAPY ON THE QUALITY-OF-LIFE [J].
CROOG, SH ;
LEVINE, S ;
TESTA, MA ;
BROWN, B ;
BULPITT, CJ ;
JENKINS, CD ;
KLERMAN, GL ;
WILLIAMS, GH .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (26) :1657-1664
[4]   An integrated method to determine meaningful changes in health-related quality of life [J].
Crosby, RD ;
Kolotkin, RL ;
Williams, GR .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (11) :1153-1160
[5]   Defining clinically meaningful change in health-related quality of life [J].
Crosby, RD ;
Kolotkin, RL ;
Williams, GR .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (05) :395-407
[6]  
*FDA, 2006, GUID IND PAT REP OUT
[7]   SYMPTOM STATUS AND QUALITY OF LIFE FOLLOWING PROSTATECTOMY [J].
FOWLER, FJ ;
WENNBERG, JE ;
TIMOTHY, RP ;
BARRY, MJ ;
MULLEY, AG ;
HANLEY, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (20) :3018-3022
[8]  
GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436
[9]   Methods to explain the clinical significance of health status measures [J].
Guyatt, GH ;
Osoba, D ;
Wu, AW ;
Wyrwich, KW ;
Norman, GR .
MAYO CLINIC PROCEEDINGS, 2002, 77 (04) :371-383
[10]   The concept of clinically meaningful difference in health-related quality-of-life research - How meaningful is it? [J].
Hays, RD ;
Woolley, JM .
PHARMACOECONOMICS, 2000, 18 (05) :419-423